Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Rating) – Cantor Fitzgerald lifted their FY2023 EPS estimates for Aytu BioPharma in a research report issued on Wednesday, November 16th. Cantor Fitzgerald analyst J. Kim now anticipates that the company will earn ($0.26) per share for the year, up from their previous estimate of ($0.54). The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.49) per share.
Aytu BioPharma (NASDAQ:AYTU – Get Rating) last posted its quarterly earnings results on Tuesday, September 27th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $27.45 million for the quarter, compared to the consensus estimate of $25.70 million. Aytu BioPharma had a negative net margin of 83.18% and a negative return on equity of 47.20%.
Aytu BioPharma Price Performance
Hedge Funds Weigh In On Aytu BioPharma
Several institutional investors have recently added to or reduced their stakes in AYTU. Commonwealth Equity Services LLC boosted its position in Aytu BioPharma by 91.0% during the third quarter. Commonwealth Equity Services LLC now owns 209,558 shares of the company’s stock worth $38,000 after purchasing an additional 99,859 shares during the period. Renaissance Technologies LLC boosted its position in Aytu BioPharma by 65.5% during the third quarter. Renaissance Technologies LLC now owns 1,747,520 shares of the company’s stock worth $323,000 after purchasing an additional 691,738 shares during the period. Finally, Prudential Financial Inc. boosted its position in Aytu BioPharma by 257.2% during the third quarter. Prudential Financial Inc. now owns 145,550 shares of the company’s stock worth $27,000 after purchasing an additional 104,800 shares during the period. Institutional investors own 18.05% of the company’s stock.
About Aytu BioPharma
Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old.
- Get a free copy of the StockNews.com research report on Aytu BioPharma (AYTU)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.